Target and Its Patented Drug(s)
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T70977 | Target Info | |||
| Target Name | Glycogen synthase kinase-3 beta (GSK-3B) | ||||
| Synonyms | Serine/threonine-protein kinase GSK3B; GSK-3 beta | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | GSK3B | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | |||||
| Patent ID | WO2014050779 | ||||
| Title | Combination of Gsk3 Inhibitor and Anti-Dr5 Antibody. | ||||
| Applicant(s) | Daiichi Sankyo Company, Limited | ||||
| Representative Drug(s) | D0Z1DH | Drug Info | N.A. | [1] | |
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.